Genome Editing Market - Global Forecast 2026-2032

The Genome Editing Market is projected to reach USD 11.59 Billion in 2026. It is expected to continue growing at a CAGR of 10.96%, reaching USD 21.71 Billion by 2032.

Genome editing has moved from a research breakthrough to a clinical and commercial capability for therapeutic innovators. CRISPR-Cas systems, zinc finger nucleases, TALENs, base editing, prime editing, and RNA-guided epigenetic editing are reshaping how pharmaceutical and biotechnology developers address monogenic disease, oncology, immunology, infectious disease, ophthalmology, and rare disorders.

The sector gained major clinical validation when CRISPR-based exa-cel received landmark regulatory authorizations for sickle cell disease and transfusion-dependent beta thalassemia in 2023 and 2024, including approvals by the U.S. FDA, the U.K. MHRA, the European Commission, and other national authorities. For therapy developers, the genome editing landscape is now defined by clinical differentiation, delivery efficiency, off-target risk management, scalable manufacturing, ethical governance, and durable evidence generation.

Transformative Shifts in the Therapeutic Landscape

The genome editing landscape is shifting from first-generation nuclease cutting toward higher-precision modalities. Base editing enables single-letter DNA changes without double-strand breaks, while prime editing broadens programmable correction potential by supporting targeted insertions, deletions, and substitutions. These approaches are accelerating pipeline expansion across hematology, liver disease, ophthalmology, oncology, immune-mediated disorders, and inherited metabolic conditions.

Commercial strategy is also changing. Ex vivo editing benefits from controlled manufacturing and established cell therapy infrastructure, while in vivo genome editing depends on safer delivery through lipid nanoparticles, viral vectors, and tissue-targeted systems. Regulatory expectations increasingly emphasize long-term follow-up, validated off-target assays, transparent patient monitoring, product comparability, and risk-based assessment of permanent genomic changes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding progress across the genome editing value chain. Machine learning models are used to design guide RNAs, predict on-target efficiency, assess off-target activity, optimize editor architecture, identify pathogenic variants, and prioritize targets with stronger disease relevance. Public advances in protein structure prediction, including AlphaFold-enabled biology, have also accelerated enzyme engineering, functional annotation, and target validation.

For therapeutic developers, AI reduces experimental search space but does not replace wet-lab validation. The strongest competitive advantage comes from combining high-quality genomic datasets, single-cell and multi-omics data, functional screens, clinically annotated cohorts, and rigorous bioinformatics with compliant model governance that supports reproducible, regulator-ready evidence.

Key Regional Insights for Genome Editing

North America remains a therapeutic genome editing leader due to deep biomedical funding, major academic medical centers, FDA experience in gene and cell therapy review, mature clinical trial infrastructure, and established GMP biomanufacturing capacity. Europe combines strong biomedical research with EMA oversight, national health technology assessment requirements, General Data Protection Regulation-driven data governance, and strict ethical expectations around germline editing. Asia-Pacific is advancing rapidly, led by China, Japan, South Korea, Australia, and India, with strong clinical research capacity, expanding precision medicine programs, and growing policy attention to biotechnology self-sufficiency.

Latin America is building relevance through Brazil and Mexico, especially in clinical research participation, public health genomics, and agricultural biotechnology spillovers. The Middle East is investing in genomic medicine through national programs in Saudi Arabia, the UAE, Qatar, and other Gulf states, strengthening sequencing infrastructure and specialty care pathways. Africa’s opportunity is tied to inherited blood disorders, infectious disease, crop resilience, and capacity-building initiatives, although laboratory infrastructure, financing, and regulatory harmonization remain uneven across the region.

Key Group Insights Across Strategic Alliances

The G7 anchors much of the therapeutic genome editing ecosystem through public research funding, regulatory precedent, intellectual property generation, clinical trial density, and advanced biomanufacturing. The European Union plays a central role in harmonized medicines regulation, cross-border research governance, data protection, ethics oversight, and ongoing policy debates over new genomic techniques in agriculture and health. NATO economies increasingly view synthetic biology and genome editing through a dual-use and biosecurity lens, supporting stronger safeguards for sensitive research, biological data, and enabling technologies.

BRICS countries are important for scale, clinical recruitment, agricultural application, public health genomics, and cost-efficient R&D, with China, India, and Brazil particularly influential. ASEAN is emerging through biomedical research hubs in Singapore, Thailand, and Malaysia, while food security, aquaculture, and infectious disease priorities support broader regional relevance. The GCC is using national genomics initiatives, hospital modernization, and precision medicine programs to create demand for advanced diagnostics, cell therapies, rare disease management, and future genome editing partnerships.

Key Country Insights for Genome Editing Adoption

The United States leads in clinical translation, FDA precedents, venture-backed biotechnology, academic spinouts, and advanced cell and gene therapy manufacturing. Canada contributes strength in genomics, stem cell research, population health data, and clinical networks, while Mexico offers expanding trial capacity, cross-border healthcare relevance, and regional manufacturing potential. Brazil is the Latin American anchor for biotechnology oversight, research scale, agricultural biotechnology experience, and large patient population access.

In Europe, the United Kingdom remains influential through MHRA innovation pathways, national genomics infrastructure, and translational research networks, while Germany and France bring pharmaceutical depth, public research institutes, advanced engineering, and biomanufacturing capability. Italy and Spain support clinical research, rare disease networks, and hospital-based translational medicine, while Russia maintains scientific capacity in molecular biology and biotechnology despite geopolitical constraints. In Asia-Pacific, China is a major clinical research and manufacturing force, India is expanding genomics, bioeconomy policy, and gene editing applications for agriculture and health, Japan offers regenerative medicine expertise and a structured regulatory pathway for advanced therapies, Australia provides strong translational research and clinical trial quality, and South Korea brings advanced biopharma, digital health integration, and CDMO capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications where genome editing offers clear clinical superiority over existing therapy, such as one-time functional cures, durable remission, reduced treatment burden, or differentiated safety. Delivery strategy should be treated as a core platform asset, not a supporting technology, because tissue targeting, payload constraints, biodistribution, and immune response management often determine clinical feasibility.

Developers should invest early in off-target detection, long-term follow-up systems, scalable GMP manufacturing, payer evidence packages, patient access planning, and ethical review processes. Strategic partnerships with AI platform specialists, academic genome centers, CDMOs, clinical trial networks, and patient advocacy organizations can shorten development timelines while improving credibility with regulators, clinicians, and payers.

Research Methodology

This executive summary is grounded in secondary research from verified public sources, including regulatory agency releases, peer-reviewed literature, clinical trial registries, government policy documents, public health guidance, and technical publications on genome editing, gene therapy, and advanced therapeutics. Insights reflect documented milestones such as CRISPR therapeutic approvals, WHO governance recommendations, national regulatory frameworks, and peer-reviewed evidence on editing efficiency, delivery systems, and safety evaluation.

The analysis synthesizes technology adoption, regional readiness, clinical translation, manufacturing feasibility, policy signals, and ethical governance. No unsupported revenue estimates are used; emphasis is placed on validated developments, observable investment and research patterns, approved products, clinical-stage activity, public regulatory positions, and reproducible scientific evidence.

Conclusion

Genome editing is entering a more disciplined phase in which scientific novelty must translate into safe, durable, manufacturable, ethically governed, and reimbursable products. The first CRISPR therapy approvals proved that programmable editing can reach patients, but broader adoption will depend on delivery innovation, regulatory trust, manufacturing scale, long-term safety monitoring, and clinical evidence quality.

Therapeutic leaders that integrate AI-enabled design, robust validation, ethical governance, and global access strategy will be better positioned to build sustainable advantage. The next phase of genome editing will reward organizations that move beyond platform promise and demonstrate measurable patient outcomes across well-defined clinical settings.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Genome Editing Market, by Technology

7.1. Introduction
7.2. Base Editing
7.2.1. Adenine Base Editor
7.2.2. Cytosine Base Editor
7.3. CRISPR
7.3.1. Cas12
7.3.2. Cas13
7.3.3. Cas9
7.4. MegaTAL
7.5. Prime Editing
7.6. TALEN
7.7. ZFN

8. Genome Editing Market, by Therapeutic Area

8.1. Introduction
8.2. Cardiology
8.3. Genetic Disorders
8.4. Infectious Diseases
8.5. Neurology
8.6. Oncology

9. Genome Editing Market, by Delivery Method

9.1. Introduction
9.2. Nonviral
9.2.1. Electroporation
9.2.2. Lipid Nanoparticles
9.3. Physical Methods
9.3.1. Gene Gun
9.3.2. Microinjection
9.4. Viral Vector

10. Genome Editing Market, by Application

10.1. Introduction
10.2. Agricultural
10.2.1. Crop Improvement
10.2.2. Livestock Improvement
10.3. Industrial Biotechnology
10.3.1. Biofuels
10.3.2. Biomanufacturing
10.4. Research
10.4.1. Basic Research
10.4.2. Drug Discovery
10.5. Therapeutics
10.5.1. Cell Therapy
10.5.2. Gene Therapy

11. Genome Editing Market, by End User

11.1. Introduction
11.2. Academic Institutes
11.3. Contract Research Organizations
11.4. Pharmaceutical Biotech

12. Genome Editing Market, by Region

12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East

13. Genome Editing Market, by Group

13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC

14. Genome Editing Market, by Country

14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Agilent Technologies, Inc.
16.2. AMS Biotechnology Ltd.
16.3. Arbor Biotechnologies Inc
16.4. Beam Therapeutics Inc.
16.5. Caribou Biosciences Inc.
16.6. Cellectis SA
16.7. Century Therapeutics Inc
16.8. Creative Biogene
16.9. CRISPR Therapeutics AG
16.10. Danaher Corporation
16.11. Editas Medicine Inc
16.12. GenScript
16.13. Gilead Sciences Inc
16.14. Horizon Discovery Group PLC
16.15. Intellia Therapeutics Inc
16.16. Lonza Group Ltd.
16.17. Mammoth Biosciences
16.18. Merck KGaA
16.19. Metagenomi
16.20. New England Biolabs, Inc.
16.21. OriGene Technologies, Inc.
16.22. Poseida Therapeutics Inc
16.23. Precision BioSciences Inc
16.24. Prime Medicine Inc
16.25. Regeneron Pharmaceuticals Inc
16.26. Sangamo Therapeutics Inc
16.27. Scribe Therapeutics
16.28. Synthego Corporation
16.29. Takara Bio Inc.
16.30. Tessera Therapeutics Inc
16.31. Thermo Fisher Scientific Inc
16.32. Vertex Pharmaceuticals Incorporated
16.33. Verve Therapeutics Inc

List of Figures

FIGURE 1. GLOBAL GENOME EDITING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GENOME EDITING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GENOME EDITING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GENOME EDITING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GENOME EDITING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GENOME EDITING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL GENOME EDITING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL GENOME EDITING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BASE EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BASE EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BASE EDITING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ADENINE BASE EDITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ADENINE BASE EDITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ADENINE BASE EDITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CYTOSINE BASE EDITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CYTOSINE BASE EDITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CYTOSINE BASE EDITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CRISPR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CRISPR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CRISPR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CAS12 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CAS12 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CAS12 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CAS13 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CAS13 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CAS13 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CAS9 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CAS9 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CAS9 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MEGATAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MEGATAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MEGATAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PRIME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PRIME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PRIME EDITING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TALEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TALEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TALEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ZFN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ZFN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ZFN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL NONVIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NONVIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL NONVIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ELECTROPORATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ELECTROPORATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ELECTROPORATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PHYSICAL METHODS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PHYSICAL METHODS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PHYSICAL METHODS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GENE GUN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GENE GUN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GENE GUN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MICROINJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL MICROINJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL MICROINJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL AGRICULTURAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL AGRICULTURAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL AGRICULTURAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CROP IMPROVEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CROP IMPROVEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CROP IMPROVEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL LIVESTOCK IMPROVEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LIVESTOCK IMPROVEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LIVESTOCK IMPROVEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL BIOFUELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BIOFUELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BIOFUELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL BIOMANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL BIOMANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL PHARMACEUTICAL BIOTECH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL PHARMACEUTICAL BIOTECH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL PHARMACEUTICAL BIOTECH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. EUROPE GENOME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. EUROPE GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 139. EUROPE GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 140. EUROPE GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 141. EUROPE GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 142. EUROPE GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 143. EUROPE GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 144. EUROPE GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 145. EUROPE GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 146. EUROPE GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 147. EUROPE GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 148. EUROPE GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 149. EUROPE GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 150. EUROPE GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA GENOME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA GENOME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. AFRICA GENOME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 180. AFRICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 181. AFRICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 182. AFRICA GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 183. AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 184. AFRICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 185. AFRICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 186. AFRICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 187. AFRICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. AFRICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 189. AFRICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 190. AFRICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 191. AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 192. AFRICA GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST GENOME EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. NATO GENOME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. NATO GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 210. NATO GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 211. NATO GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 212. NATO GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 213. NATO GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 214. NATO GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 215. NATO GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 216. NATO GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 217. NATO GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 218. NATO GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 219. NATO GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 220. NATO GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 221. NATO GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. G7 GENOME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 223. G7 GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 224. G7 GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 225. G7 GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 226. G7 GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 227. G7 GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 228. G7 GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 229. G7 GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 230. G7 GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 231. G7 GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 232. G7 GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 233. G7 GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 234. G7 GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 235. G7 GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. BRICS GENOME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 237. BRICS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 238. BRICS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 239. BRICS GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 240. BRICS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 241. BRICS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 242. BRICS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 243. BRICS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 244. BRICS GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 245. BRICS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 246. BRICS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 247. BRICS GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 248. BRICS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 249. BRICS GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. ASEAN GENOME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 265. ASEAN GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 266. ASEAN GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 267. ASEAN GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 268. ASEAN GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 269. ASEAN GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 270. ASEAN GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 271. ASEAN GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 272. ASEAN GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. ASEAN GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 274. ASEAN GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 275. ASEAN GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 276. ASEAN GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 277. ASEAN GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. GCC GENOME EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 279. GCC GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 280. GCC GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 281. GCC GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 282. GCC GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 283. GCC GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 284. GCC GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 285. GCC GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 286. GCC GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 287. GCC GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 288. GCC GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 289. GCC GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 290. GCC GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 291. GCC GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 293. CHINA GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 294. CHINA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 295. CHINA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 296. CHINA GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 297. CHINA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 298. CHINA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 299. CHINA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 300. CHINA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 301. CHINA GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 302. CHINA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 303. CHINA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 304. CHINA GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 305. CHINA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 306. CHINA GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. UNITED STATES GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. UNITED STATES GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 309. UNITED STATES GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 310. UNITED STATES GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 312. UNITED STATES GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 313. UNITED STATES GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 314. UNITED STATES GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 315. UNITED STATES GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. JAPAN GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 322. JAPAN GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 323. JAPAN GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 324. JAPAN GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 325. JAPAN GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 326. JAPAN GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 327. JAPAN GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 328. JAPAN GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 329. JAPAN GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 330. JAPAN GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 331. JAPAN GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 332. JAPAN GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 333. JAPAN GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 334. JAPAN GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. INDIA GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. INDIA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 337. INDIA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 338. INDIA GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 339. INDIA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 340. INDIA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 341. INDIA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 342. INDIA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 343. INDIA GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 344. INDIA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 345. INDIA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 346. INDIA GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 347. INDIA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 348. INDIA GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 349. GERMANY GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 350. GERMANY GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 351. GERMANY GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 352. GERMANY GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 353. GERMANY GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 354. GERMANY GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 355. GERMANY GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 356. GERMANY GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 357. GERMANY GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 358. GERMANY GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 359. GERMANY GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 360. GERMANY GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 361. GERMANY GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 362. GERMANY GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 363. UNITED KINGDOM GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 364. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 365. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 366. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 367. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 368. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 369. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 370. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2017-2032 (USD MILLION)
TABLE 371. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 372. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2017-2032 (USD MILLION)
TABLE 373. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 374. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY RESEARCH, 2017-2032 (USD MILLION)
TABLE 375. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 376. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 377. AUSTRALIA GENOME EDITING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 378. AUSTRALIA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 379. AUSTRALIA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2017-2032 (USD MILLION)
TABLE 380. AUSTRALIA GENOME EDITING MARKET SIZE, BY CRISPR, 2017-2032 (USD MILLION)
TABLE 381. AUSTRALIA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 382. AUSTRALIA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 383. AUSTRALIA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2017-2032 (USD MILLION)
TABLE 384. AUSTRALIA GENOME EDITING MARKET SIZE, BY PHYSICAL

Companies Mentioned

Agilent Technologies, Inc.
AMS Biotechnology Ltd.
Arbor Biotechnologies Inc
Beam Therapeutics Inc.
Caribou Biosciences Inc.
Cellectis SA
Century Therapeutics Inc
Creative Biogene
CRISPR Therapeutics AG
Danaher Corporation
Editas Medicine Inc
GenScript
Gilead Sciences Inc
Horizon Discovery Group PLC
Intellia Therapeutics Inc
Lonza Group Ltd.
Mammoth Biosciences
Merck KGaA
Metagenomi
New England Biolabs, Inc.
OriGene Technologies, Inc.
Poseida Therapeutics Inc
Precision BioSciences Inc
Prime Medicine Inc
Regeneron Pharmaceuticals Inc
Sangamo Therapeutics Inc
Scribe Therapeutics
Synthego Corporation
Takara Bio Inc.
Tessera Therapeutics Inc
Thermo Fisher Scientific Inc
Vertex Pharmaceuticals Incorporated
Verve Therapeutics Inc

Table Information

Report Attribute	Details
No. of Pages	193
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 11.59 Billion
Forecasted Market Value ( USD ) by 2032	$ 21.71 Billion
Compound Annual Growth Rate	10.9%
Regions Covered	Global
No. of Companies Mentioned	33

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in the Therapeutic Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights for Genome Editing

Key Group Insights Across Strategic Alliances

Key Country Insights for Genome Editing Adoption

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Mutation Detection Kits In Genome Editing Market - Global Forecast 2026-2032

Genome Engineering Market - Global Forecast 2026-2032

Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR/Cas9, ZFN), Delivery Method (Ex Vivo, in Vivo), Application (Genetic Engineering, Clinical Applications), Mode, End Use, and Region with Growth Forecasts, 2026-2033

Genome Editing Market Size, Share & Growth Analysis Report - Industry Trends, Competitive Landscape, Segment Insights and Forecast 2024-2034

Genome Editing / Genome Engineering - Global Strategic Business Report